Experts in treating prostate cancer highlight recent clinical data and discuss practical implications for patient care.
EP. 1: Castration Resistance Monitoring in Prostrate Cancer
EP. 2: Bone Health While Receiving ADT For Prostate Cancer
EP. 3: Cardiovascular Risk Related to ADT Therapy in Prostate Cancer
EP. 4: Oral LHRH Treatment for Prostate Cancer
EP. 5: Key Data for the Treatment of mCSPC
EP. 6: Androgen Receptor Blocker Use in mCSPC
EP. 7: Identifying Appropriate Therapy for Patients in Prostate Cancer
EP. 8: Clinical Trial Data for the Treatment of nmCRPC
EP. 9: The Importance of Treating nmCRPC
EP. 10: The Importance of Scans, NGS, and Imaging in nmCRPC
EP. 11: Treating Oligometastatic Prostate Cancer
EP. 12: The Current and Emerging Treatment Landscape of mCRPC
EP. 13: Germline and Somatic Testing in mCRPC
FDA accepts NDA for new formulation of piflufolastat F 18 in prostate cancer
First-line disitamab vedotin plus toripalimab under review in China for la/mUC
BCG/ICI combinations offer potential paradigm shift in BCG-naïve NMIBC
Intravesical gemcitabine/docetaxel formulation shows encouraging efficacy in NMIBC